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Display antigens MRI contrast
Graphical abstract
Gas vesicles are produced by a wide range of bacteria and archaea. Once purified they can be used to display antigens in vac-
cines and as ultrasound contrast agents. Gas vesicle collapse is also a possible method to control cyanobacterial blooms.
Abstract
A range of bacteria and archaea produce gas vesicles as a means to facilitate flotation. These gas vesicles have been purified 
from a number of species and their applications in biotechnology and medicine are reviewed here. Halobacterium sp. NRC-1 gas 
vesicles have been engineered to display antigens from eukaryotic, bacterial and viral pathogens. The ability of these recom-
binant nanoparticles to generate an immune response has been quantified both in vitro and in vivo. These gas vesicles, along 
with those purified from Anabaena flos- aquae and Bacillus megaterium, have been developed as an acoustic reporter system. 
This system utilizes the ability of gas vesicles to retain gas within a stable, rigid structure to produce contrast upon exposure 
to ultrasound. The susceptibility of gas vesicles to collapse when exposed to excess pressure has also been proposed as a bio-
control mechanism to disperse cyanobacterial blooms, providing an environmental function for these structures.
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IntRoductIon
Gas vesicles are hollow, proteinaceous, intracellular organelles 
that are produced by a range of bacteria and archaea [1]. They 
were first discovered in cyanobacteria through their tendency 
to conglomerate in the formation of gas ‘vacuoles’ that refract 
light [2]. Cyanobacteria that can make gas vesicles include 
Anabaena flos- aquae, Planktothrix rubescens and Microcystis 
species [3]. Gas vesicles have also been identified in a range 
of heterotrophic bacteria, including Psychromonas ingrahamii 
[4], Serratia sp. ATCC 39006 [5], Bacillus megaterium [6] and 
Streptomyces sp. CB03234- S [7]. Archaea that produce gas 
vesicles include halophiles such as Halobacterium salinarum 
[8], Haloferax mediterranei [9] and Haloquadratum walsbyi 
[10, 11].
The genes required for gas vesicle production have been iden-
tified in a range of species. While there is homology between 
some of the core gas vesicle genes, there is also significant vari-
ation in the genes required for gas vesicle formation between 
organisms [1]. In Halobacterium species NRC-1 there are 
two gas vesicle gene clusters present, on plasmids pNRC100 
(gvp1) and pNRC200 (gvp2) [12–15]. Each of these clusters 
contain 14 genes in 2 divergently transcribed operons [13, 16]. 
In contrast, the Anabaena flos- aquae gas vesicle gene cluster 
consists of five copies of gvpA and homologues of six other 
gas vesicles genes [17, 18]. In Serratia sp. ATCC39006 the gas 
vesicle cluster is comprised of 19 genes in 2 operons, of which 
11 are essential for gas vesicle production [5, 19]. The gas 
vesicle gene clusters of Serratia sp. ATCC39006 and Bacillus 
megaterium have been expressed in Escherichia coli and gas 
vesicle structures have been observed in the heterologous host 
[5, 6]. The functions of some gas vesicle genes are conserved 
between species and have been well characterized, such as 
gvpA and gvpC, which encode the core structural protein and 
secondary strengthening protein, respectively. However, there 
are multiple genes of unknown function in various gas vesicle 
loci, some of which are predicted to encode minor structural 
proteins or play a regulatory role [19, 20].
Gas vesicle size and shape varies depending on both the 
organism and the environmental conditions. Individual gas 
vesicles tend to be 0.045–0.2 µm wide and 0.1–2 µm long [1]. 
Vesicles initially form as small bicone structures that then 
extend to become spindle- or cylindrical- shaped mature gas 
vesicles (Fig. 1a) [3]. The core gas vesicle protein, GvpA, is a 
Fig. 1. Gas vesicle development and appearance. (a) Gas vesicles develop from small bicone structures into mature spindle/cylindrical 
structures. (b) Transmission electron micrograph of mature gas vesicles inside a Serratia sp. ATCC 39006 cell.
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7–8 kDa protein that assembles into 4.6 nm wide ribs that run 
perpendicular to the long axis of the vesicle and the 2 nm thick 
vesicle wall is composed of a single layer of this hydrophobic 
protein [3, 21]. The wall of the gas vesicle excludes water but 
allows gas to diffuse freely across it [22, 23]. A secondary gas 
vesicle protein, GvpC, is often found forming a mesh over the 
exterior surface of gas vesicles, strengthening the structure 
[24–26].
Gas vesicles increase the buoyancy of cells and, when present 
in sufficient quantity, facilitate upward flotation in static water 
columns [3]. Gas vesicles collapse when exposed to pressure 
that exceeds the ‘critical collapse pressure’, thereby reducing 
the buoyancy of the cell [2, 3]. The critical collapse pressure 
of gas vesicles can be measured using pressure nephelom-
etry and varies depending on the dimensions of the vesicles 
[27]. Nephelometry has also been used to demonstrate the 
strengthening effect of the GvpC structural protein on gas 
vesicles [19]. Narrower gas vesicles tend to be found in organ-
isms that grow in deeper environments and are more resistant 
to collapse under hydrostatic pressure [27].
Individual gas vesicles can be visualized within cells using 
transmission electron microscopy (Fig. 1b). Gas vesicles have 
been purified from various organisms to determine their 
structure and protein composition [28–32] and there is a 
growing interest in the use of gas vesicles for biotechnological, 
medical and ecological applications. For example, gas vesicles 
are being investigated as antigen delivery vehicles, where 
promising results have already been observed in a range of 
systems [33]. Gas vesicles are under investigation as contrast 
agents for use in magnetic resonance imaging (MRI) and they 
have been proposed as a target for disrupting cyanobacte-
rial blooms by exploiting ultrasonic collapse of the vesicles 
[34, 35]. This review will focus on the potential applications 
of gas vesicles, what has been achieved so far and prospects 
for future applications.
the use of gas vesicles in engineering vaccines
Purified gas vesicles engineered to also display an antigen of 
interest, known as gas vesicle nanoparticles (GVNPs), can 
offer advantages over other vaccine types, including increased 
stability, immunogenicity and enhanced uptake across cell 
membranes [36–38]. Use of GVNPs can also avoid some of 
the downsides of live- attenuated vaccines, including a lower 
risk of infection, and they have the therapeutic potential to be 
given to immunocompromised individuals [33, 37].
Gas vesicles were first proposed as an antigen delivery system 
nearly 20 years ago and have since been engineered to display 
antigens from viruses, bacteria and eukaryotes [33, 39]. Most 
of this work has been performed using purified gas vesicles 
from the halophilic archaeon, Halobacterium sp. NRC-1 
[40–45]. Halobacterium gas vesicles are an ideal vaccine 
component due to their biological stability and resistance 
to chemical or enzymatic degradation, thereby allowing 
sustained presentation of the epitope of interest [39]. The 
creation of a range vectors containing the gas vesicle genes 
enables facile genetic manipulation and production of recom-
binant GVNPs at low cost [14, 39, 46, 47].
The basic structure of Halobacterium gas vesicles involves a 
highly organized rib structure of GvpA with GvpC located 
on the outer surface of the vesicle, providing stability and 
strengthening the structure [48–50]. Modelling studies have 
suggested that GvpA forms a hydrophobic surface on the 
inside of the gas vesicle while the external surface is hydro-
philic [49, 51]. The acidic tail of GvpC is predicted to be 
important for protein stability in high- saline conditions and 
has also been investigated as a region capable of tolerating 
insertions of antigenic peptides [39]. Previous studies using 
Halobacterium sp. NRC-1 established methods for scaling up 
the production and purification of gas vesicles [13, 52, 53]. 
Low- speed centrifugation overnight of lysed Halobacterium 
cells allows the buoyant organelles that rise to the air/liquid 
interface to be removed and purified [39].
Gas vesicles purified from Halobacterium sp. NRC-1 were 
initially tested without any alterations to determine their 
immunogenicity before specific alterations to GvpC were 
investigated [39]. For this study, a gas vesicle- deficient strain 
of Halobacterium sp. NRC-1, SD109, was transformed with 
the pFL2 vector for gas vesicle purification [39, 54, 55]. 
Strain SD109 is a spontaneous gas vesicle- negative mutant 
of Halobacterium sp. NRC-1 that has the entire gas vesicle 
gene cluster deleted [54, 55]. The pFL2 vector is an E. coli–
Halobacterium shuttle plasmid that contains a 13 kb gvp 
gene fragment, which is sufficient to complement the gas 
vesicle- negative phenotype of strain SD109 and includes a 
selectable marker for mevinolin [39, 56]. Gas vesicles puri-
fied from Halobacterium strain SD109 carrying pFL2 were 
tested to determine their immunogenicity without alteration 
and after chemical conjugation of the trinitrophenol (TNP) 
hapten [39]. Experiments performed in mice showed that 
wild- type gas vesicles stimulated an immune response but 
had no negative impact in terms of mouse survival, or any 
obvious indications of toxicity [39, 42]. Only the TNP conju-
gated vesicles elicited a TNP- specific antibody response [39]. 
No external adjuvant was used in conjunction with the gas 
vesicle preparations, indicating that gas vesicles are capable 
of acting as both an adjuvant and an antigen delivery system 
[39]. After demonstrating that gas vesicles could function as 
an antigen carrier, the ability of GvpC to tolerate insertions 
while remaining functional and antigenic was tested using an 
18 base pair insertion in the C- terminus of the gene [39, 56]. 
Mice injected with the recombinant gas vesicles displayed 
a specific immune response against the inserted ESSGTF 
peptide [39].
This system was then used to express and display simian 
immunodeficiency virus (SIV) antigens on gas vesicles and 
monitor the immune response elicited [42]. The insertions 
ranged in length from 17 to 235 amino acids of the SIV Gag 
protein, much larger than previously described GvpC inser-
tions [39, 42, 56]. The Gag protein was selected as an antigen 
as it is a precursor to one of the core structural proteins of SIV 
[57, 58]. These recombinant SIV–GVNPs were recognized by 
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antibodies produced by SIV- infected monkeys in an enzyme- 
linked immunosorbent assay (ELISA), indicating that the Gag 
protein segment adopted an immunologically recognizable 
conformation on the gas vesicle [42, 50]. Subsequent tests in 
mice found a long- lived immune response, with antibodies 
detected 120 days after a booster injection and a rapid IgG 
response 10 days after a second booster [42].
After the successful expression of the SIV Gag protein on 
the surface of Halobacterium sp. NRC-1 gas vesicles, further 
work was carried out to express different SIV proteins on 
recombinant GVNPs and determine their potential use in 
vaccines [42, 50]. Recombinant SIV–GVNP fusions were 
made, expressing different SIV proteins, Tat, Rev and Nef1 
[50]. The Tat protein is produced early in the virus life cycle 
and is required for viral replication, and the homologue in 
human immunodeficiency virus (HIV) has been proposed 
as a vaccine target [59, 60]. Rev and Nef1 are found in the 
host cell nucleus and membrane, respectively, and have 
also been identified as important potential targets for HIV 
vaccines [61–64]. The Tat/Rev/Nef1 recombinant gas vesicles 
were confirmed as functional through flotation tests before 
Western blots were used to show that the SIV–GVNPs were 
larger than wild- type [50]. Specific anti- Tat/Rev/Nef1 mouse 
antibodies could recognize the appropriate SIV–GVNPs but 
not wild- type GVNPs [50]. Anti- GvpC tests were positive for 
all gas vesicles – wild- type and recombinant [50].
ELISAs were used to determine the immune response of mice 
injected with one of the three types of SIV–GVNPs and the 
strongest immune response was shown by GVNPs displaying 
a portion of the Tat protein [50]. From cultured macrophages, 
the cytokines produced following exposure to these GNVPs 
that displayed SIV epitopes were also investigated [65]. Using 
archived sera samples, the specific antibody isotype was deter-
mined for the GVNPs displaying fragments of the Tet, Rev 
and Nef1 SIV proteins, with IgG1 the predominant isotype 
[50, 65]. The dominant cytokines released throughout the 
immunization process were IL-10 and IL-12, which peaked 
after 12 h for the GVNPs displaying Tat and Rev [65]. For 
Nef1- GVNPs, the IL10 response peaked after 24 h and was at a 
much higher level [65]. This work also tracked the time taken 
for gas vesicles to degrade within macrophages, by visualizing 
clusters of immunostained GVNPs [65]. Along with Western 
blots, the study showed that the Tat, Rev and Nef1 proteins 
were degraded at a much faster rate than the GvpC proteins, 
which, although partially degraded, still remained at detect-
able levels within macrophages after 120 h [65].
This recombinant approach was subsequently used to produce 
GVNPs displaying three different outer- membrane proteins 
from Chlamydia trachomatis [66]. These proteins were: the 
major outer membrane protein (MOMP), outer membrane 
complex B (OcmB) and polymorphic outer- membrane protein 
D (PompD), each of which have been proposed to have roles 
in the virulence of C. trachomatis and have been suggested 
as potential vaccine candidates [67–69]. Western blots 
performed using anti- GvpC and anti- Chlamydia antibodies, 
as well as sera from patients with Chlamydia infections, were 
used to detect the presence of MOMP, PompD and OcmB 
fragments on the surface of the GVNPs [66]. The GVNPs 
were confirmed to have been taken up by the cells using 
immunostained human foreskin fibroblast cells, where the 
nanoparticles were broken down and the Chlamydia antigens 
displayed on the cell surface [66].
Recombinant GVNPs have also been produced displaying 
fragments of the Salmonella enterica serovar Typhi SopB 
protein and a Plasmodium falciparum enolase [40, 43–45]. 
Current vaccines for Salmonella enterica serovar Typhi use 
the Vi capsular polysaccharide subunit or live- attenuated 
vaccines [70]. However, the effectiveness of these vaccines 
is reduced by the need for multiple doses and there are also 
stability issues [70]. GVNPs were developed as an alternative 
Salmonella enterica vaccine candidate, with fragments of the 
secreted effector protein, SopB, fused to GvpC [40]. The sopB 
gene fragments were codon- optimized for expression in Halo-
bacterium and the protein conformation on the GVNP was 
tested using antigen- specific sera [40]. For the first time using 
a recombinant GVNP vaccine, a live challenge was adminis-
tered whereby mice were exposed to 107 virulent Salmonella 
after the mice had been immunized and received a booster of 
the GVNP SopB vaccine [40]. A significant immune response 
was observed with increases in IFN-γ, IL-2 and IL-9, along 
with a reduction in the bacterial load of mice exposed to the 
vaccine compared with the NRC-1 GVNP control [40, 43]. 
The bacterial counts from the spleen, liver and mesenteric 
lymph nodes of mice exposed to the GVNP- SopB vaccine 
were reduced by at least two orders of magnitude [40, 43].
In P. falciparum work carried out by Dutta et al. an enolase was 
used as an antigen, as this protein had been found to localize 
to the cell surface in multiple stages of the P. falciparum life 
cycle [71]. A 15 amino acid peptide from the enolase enzyme 
was cloned into the previously described GVNP display 
system and the recombinant GNVPs were used to immunize 
mice before they were challenged with the murine parasite, 
Plasmodium yoelii [44]. Mice that were not immunized or 
were immunized with wild- type GVNPs showed significantly 
higher levels of parasitaemia compared to those found with 
the recombinant GVNPs displaying the enolase fragment 
[44]. Survival of mice immunized with the recombinant 
GVNPs was also significantly increased compared to that of 
the control groups [44].
In a recent study, the ability of recombinant GVNPs to 
rescue mice from endotoxic shock was determined, with 
promising results [41]. This was assessed using GVNPs 
displaying a fragment of the murine bactericidal/permeability 
increasing protein (BPI), an endotoxin neutralizing molecule 
[41, 72]. The BPI protein has anti- inflammatory properties, 
as it prevents the interaction between lipopolysaccharides of 
Gram- negative bacteria and Toll- like receptor 4 [41, 72]. This 
study utilized a new GVNP expression system that allows for 
the expression of GvpC with the insert of interest on a much 
smaller plasmid that does not contain the entire Halobacte-
rium gas vesicle cluster, and is expressed in a gvpC- negative 
strain rather than a strain deleted for the entire gas vesicle 
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cluster [73, 74]. The recombinant BPI–GVNPs displayed 
antibacterial activity, killing 50–75 % of E. coli and S. typhi 
cells when incubated together, and scanning electron micros-
copy showed evidence of bacterial cell lysis and membrane 
perturbations [41]. These BPI–GVNPs also elicited in vivo 
anti- inflammatory effects, with 100 % of mice injected in the 
footpad with BPI–GVNPs 1 h before challenge with bacterial 
lipopolysaccharide surviving for at least 5 days. In contrast, 
mice injected with wild- type GVNPs died within 7 h post- 
challenge [41]. The route of injection was important to the 
effect, however, with mice injected subcutaneously showing 
no difference in survival and mice injected intraperitoneally 
with BPI–GVNPs only showing an increased survival time 
of 24 h [41]. It was suggested that these results may be due 
to differences in absorption rates of the particles into the 
bloodstream [41, 75].
The Halobacterium sp. NRC-1 gas vesicles have shown great 
potential as a means to deliver antigens in vaccines. This 
system has been used to display epitopes from a diverse panel 
of pathogens and appears to be flexible in terms of the inser-
tions tolerated in the GvpC protein, allowing for GvpC to 
retain functionality whilst antigens display the correct confor-
mation. Tests performed in vivo have shown increased survival 
and reduction of disease in both S. typhi and P. falciparum 
infection models [40, 43, 44]. Most recently, this system has 
also been used to deliver an endotoxin- neutralizing protein 
that increased mouse survival in an endotoxic shock model 
[41].
The future usefulness of this system has been greatly 
improved by the development of a more efficient method for 
creating recombinant GVNPs [73]. This will enable a wide 
range of potential vaccine candidates to be investigated. The 
potential for GVNPs to be engineered to display multiple 
proteins together on the same particle is being investigated 
and would likely have a range of biotechnological applica-
tions [33]. Although these GVNPs are incredibly useful tools, 
unanswered questions still remain regarding basic aspects 
of how they are generated and organized within the cell 
[1, 76, 77]. Further work is needed to determine the roles of 
many of the proteins involved in the production and degrada-
tion of GVNPs and the exact method for how gas vesicles 
mature from bicones to cylinders is not well understood. The 
conformation of key proteins when displaying the antigens 
described above also remains unknown. Investigations into 
the optimal delivery route for these GVNPs are ongoing, with 
one study investigating the use of micro- needles to enhance 
skin permeation of the particles, with a view to developing 
them as a drug delivery system [78].
Gas vesicles as contrast agents
There has long been interest in developing reporter genes 
that respond to magnetic resonance, analogous to geneti-
cally encoded optical reporters including the green fluores-
cent protein [79]. Due to their stable and rigid nature, gas 
vesicles have recently been developed as such a system for 
use in MRI [30, 34]. Current contrast agents for MRI and 
ultrasound are conventionally made from lipid or protein- 
stabilized gas microbubbles [34]. These microbubbles have 
limitations, as pressure gradients may lead to bubbles larger 
than 1 µm, which can result in fragmentation and subsequent 
escape of gas from the microbubbles [34, 80, 81]. This limits 
the usefulness of contrast agents when imaging vascular 
structures, as the microbubbles are unable to pass through 
the endothelium [80]. Ultrasound and MRI are capable of 
visualizing deep tissues within animal models and for human 
applications, but have few molecular reporters compared to 
optical imaging [82–84].
To test the potential to use gas vesicles as nanoscale ultrasonic 
molecular reporters, Shapiro and colleagues purified gas vesi-
cles from Anabaena flos- aquae and Halobacterium sp. NRC-1, 
before imaging gel phantoms to see the contrast produced 
[34]. They also showed that, after gas vesicles have been 
collapsed by an increase in pressure, they are no longer able 
to produce any contrast [34]. This feature of gas vesicles can 
be exploited to generate subtraction images, whereby images 
are taken before and after gas vesicle collapse, to allow better 
contrast. A greater signal was also achieved when intact A. 
flos- aquae cells were imaged with gas vesicles contained inside 
[34]. Experiments were also carried out using a mouse model, 
where Halobacterium gas vesicles were injected into mice 
subcutaneously and intravenously, and could be detected via 
ultrasound [34].
Gas vesicles have also been used as reporters for hyperpolar-
ized xenon MRI [85]. Hyperpolarized MRI is a more sensitive 
detection method that requires the presence of 129Xe, which 
can be detected in far lower concentrations than thermally 
polarized 1H, which is used in other reporter systems [85, 86]. 
Gas vesicles were purified and chemical exchange saturation 
transfer (CEST) was used to allow hyperpolarized xenon to 
diffuse into the vesicles. Gas vesicles could then be detected 
at concentrations of as low as 25 pM using this method [85]. 
The ability of GvpC to be engineered to produce gas vesicles 
with different collapse pressures was also investigated in order 
to create a range of gas vesicles with different acoustic proper-
ties that further enhance the range of ultrasound responses 
that could be realized [87]. Recombinant GvpC variants were 
expressed in E. coli and added to prepurified gas vesicles from 
A. flos- aquae that had their native GvpC proteins removed by 
treatment with 6 M urea, leaving only the GvpA shell intact 
[87]. These gas vesicles with different GvpC variants showed 
different acoustic collapse curves that could be distinguished 
from each other through imaging at different pressures [87].
The acoustic behaviour of Halobacterium sp. NRC-1 gas 
vesicles has been studied in greater detail to determine their 
suitability as contrast agents [88, 89]. These gas vesicles have 
different properties compared to those of A. flos- aquae; they 
are lemon- shaped rather than cylindrical and are wider than 
their cyanobacterial counterparts [1, 3, 88]. The acoustic 
collapse pressure of Halobacterium gas vesicles was deter-
mined at different frequencies, and was found to increase 
upon exposure to ultrasound to 620–694 kPa at 27.5 MHz 
from 522 to 576 kPa at 12.5 MHz [88, 89]. Finite element 
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modelling simulations predicted that the collapse pressure is 
in part determined by the gas permeability of the gas vesicle 
shell [88]. Gas vesicles produce a strong second harmonic 
and behave nonlinearly at acoustic pressures above and below 
the critical collapse pressure [88, 90]. This indicates that gas 
vesicles can be detected using previously established methods 
used to detect microbubbles [89]. Similar experiments were 
also carried out using A. flos- aquae gas vesicles, either in their 
native form or with the GvpC shell removed, which created a 
greater harmonic response [87, 91].
There are detectable differences in the acoustic properties of 
gas vesicles isolated from different species [30, 34, 85]. This 
opens up the prospect of multiplexing, whereby different 
populations of gas vesicles can be visualized in the same 
sample through serial collapse imaging [30, 34]. Gas vesicles 
have been isolated from three different systems, A. flos- 
aquae, Halobacterium sp. NRC-1 and E. coli heterologously 
expressing gas vesicles from Bacillus megaterium [30, 34, 85]. 
Each system required different culturing and purification 
conditions, and gas vesicles could be purified from E. coli 
cells much more quickly than from cyanobacteria or haloar-
chaea (which can take 2–3 weeks to produce gas vesicles in 
sufficient quantities) [30]. These gas vesicles have been further 
manipulated to non- invasively image bacteria, producing 
them heterologously [92]. E. coli cells were transformed with 
a set of acoustic reporter genes (ARGs) from A. flos- aquae 
(the structural genes gvpA and gvpC) and B. megaterium 
(the accessory genes gvpR- gvpU) under an IPTG- inducible 
promoter [92]. E. coli cells making these combination gas 
vesicles produced greater ultrasound contrast compared to 
GFP- producing controls and were detectable at a concentra-
tion of 5×107 cells ml−1 [92]. By varying the nature of the gvpC 
gene used, gas vesicles with differing collapse pressures were 
created and could be used to distinguish between populations 
[92]. Using a probiotic strain of E. coli, Nissle 1917, trans-
formed with the acoustic reporter genes, the gastrointestinal 
tract of mice could be imaged using ultrasound, a location 
that is difficult to image by optical techniques [92].
A recent report has described how mammalian cells have 
been engineered to produce gas vesicles in a gene expression- 
dependent manner [93]. This system allows for the first time 
a link between the expression of genes in mammalian cells 
and an acoustic reporter that can be visualized by ultrasound 
[92, 93]. This work used codon- optimized genes from B. 
megaterium that were integrated into genome of HEK293T 
cells under a doxycycline- inducible promoter, with electron 
microscopy used to show successful gas vesicle production 
[93]. These gas vesicle- producing HEK cells were then used 
to create tumours in immunocompromised mice, which were 
treated with doxycycline to promote gas vesicle expression 
[93]. Using the previously described feature of gas vesicle 
collapse above certain ultrasound pressure thresholds, it was 
shown that only cells in the periphery of the tumour that were 
exposed to blood vessels produced gas vesicles, while those 
in the core of the tumour did not [34, 87, 92, 93]. This is an 
exciting step forward in the use of gas vesicles as imaging 
tools, but the authors note that there is still work to be done 
in condensing the constructs necessary for gas vesicle expres-
sion in mammalian cells to increase the utility of this reporter 
system [93].
The use of gas vesicles as biomolecular contrast agents has 
developed rapidly in recent years, with promising results 
shown in vivo and in vitro [34, 92]. Detailed modelling and 
experimental analysis of the acoustic behaviour of these gas 
vesicles has helped to develop a system that is functional with 
gas vesicles from different host organisms and that can be 
expressed heterologously [88, 89, 91, 92]. This system is still 
being optimized, with new applications currently in develop-
ment, including the expression of gas vesicles in mammalian 
cells, the use of gas vesicles to image neural activity and the 
use of gas vesicles as optical coherence tomography contrast 
agents [92, 93]. Gas vesicles and targeted ultrasound have also 
been proposed as a means to deliver therapeutics through the 
selective destruction of engineered bacteria [94].
targeted collapse of gas vesicles as a biocontrol 
mechanism
Cyanobacteria are well known for their ability to grow in large 
blooms in the surface layers of standing water, often in lakes 
or reservoirs [95]. These blooms can be harmful to humans 
and animals that come into contact with, or consume, water 
contaminated with cyanotoxins [95]. Artificial mixing has 
been used as a method to control cyanobacterial blooms, 
as it eliminates stratification of the water, and can therefore 
change the dominant species by hampering the growth of 
cyanobacteria while favouring diatom growth [96, 97]. One 
feature that has been associated with the success of bloom- 
forming cyanobacteria is the ability to synthesize gas vesicles 
as a buoyancy aid [3, 98, 99]. The use of ultrasound to collapse 
gas vesicles has been proposed as a method to control cyano-
bacterial blooms [100]. The extent of the damage caused to 
cyanobacteria by ultrasound treatment is dependent on a 
range of factors, including the intensity and duration of the 
ultrasound and the frequency used [101]. An advantage of the 
sonication method is that it is more environmentally friendly 
than other methods to control blooms, such as the use of 
chemical algicides [101].
In an experimental setting, 3 s exposure to a 28 kHz 
frequency caused settling of 80 % of a culture of cyanobac-
teria; when assessed by transmission electron microscopy it 
was confirmed that the gas vesicles had collapsed following 
sonication [100]. A similar study found that growth of the 
gas vesicle- producing Microcystis aeruginosa was severely 
inhibited by the application of 1.7 MHz ultrasound, whilst the 
growth of Synecochoccus PCC7942 (which does not produce 
gas vesicles) was not affected [102]. Similarly, exposure to 
ultrasound of 1.7 MHz was sufficient to inhibit the growth of 
Spirulina (Arthrospira) platensis, a cyanobacterium that is not 
normally associated with bloom formation but does produce 
gas vesicles [103]. In pond and lake studies, the application 
of ultrasound and water pumps has been sufficient to control 
cyanobacterial levels without causing any death of larger 
organisms, such as fish and insects [104, 105]. However, 
507
Hill and Salmond, Microbiology 2020;166:501–509
further investigation may be necessary to determine that there 
have been no negative impacts short of death [104]. These 
outcomes were, in part, affected by the collapse of gas vesi-
cles, but gas vesicle collapse and subsequent sedimentation of 
the cells does not necessarily lead to cell death and de novo 
biogenesis of gas vesicles can occur over time [104–106]. One 
concern surrounding the use of ultrasound to control cyano-
bacterial blooms is that, in addition to collapsing gas vesicles, 
ultrasound can also cause disruption of cell membranes and 
might lead to release of cyanotoxins, such as microcystins 
[101, 107]. Although ultrasound has been shown to also break 
down some microcystins, the effect of ultrasound frequency 
on cell integrity would be an important parameter to consider 
and so would need to be monitored to avoid further contami-
nation of water [107, 108].
conclusIons
Microbial gas vesicles show great promise as tools for various 
biotechnological, medical and environmental applications. 
They have utility for the engineering of better vaccines and the 
generation of novel MRI contrast agents, and can be exploited 
in the control of cyanobacterial blooms. Gas vesicles are stable 
structures and this is one of many features that make them 
attractive as exploitable biotechnological systems. If we are 
to benefit fully from the potential use of gas vesicles, the 
fundamental structural biology and molecular biology of 
vesicle morphogenesis and regulation require more intense 
study. Nevertheless, progress thus far has been exciting and 
so it seems highly likely that future applications of bacterial 
and archaeal gas vesicles in biotechnology, medicine and the 
environment hold substantial promise.
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